Choriocarcinoma

Main study objectives To study the pharmacokinetic characteristics of a single oral administration of methotrexate tablets (test preparation, specification: 2.5 mg) provided by Hainan Zhuoke Pharmaceutical Co., Ltd. and a single oral administration of methotrexate tablets (reference preparation, trade name: METHOTREXATE®, specification: 2.5 mg) certified by Pfizer Japan Inc. under the same conditions in healthy subjects under fasting and postprandial conditions, to evaluate the bioequivalence between the two preparations and provide a basis for the registration application of the test preparation. Secondary study objectives To observe the safety of a single oral administration of one tablet of the test preparation or one tablet of the reference preparation in healthy subjects under fasting and postprandial conditions.